Brief: NeuroVive Pharmaceutical enters into global licensing agreement with Yungjin Pharm
01/05/2017 23:21
May 2 (Reuters) - Yungjin Pharm Co Ltd 003520.KS :
* announced it has entered into global licensing agreement
on Yungjin Pharm's compound KL1333 for genetic mitochondrial
disorders
* will now initiate activities in preparation for next
clinical study in Europe and/or in U.S.
* NeuroVive will pay Yungjin Pharm upfront payments of $1
million at signing
* NeuroVive will pay Yungjin Pharm additional $1 million
after completion of a successful phase I clinical trial
Source text for Eikon: urn:newsml:reuters.com:*:nWkr8kYH18
Further company coverage: 003520.KS
((Bangalore.newsroom@thomsonreuters.com;))